Vera Therapeutics price target raised to $76 from $56 at Guggenheim
Guggenheim raised the firm's price target on Vera Therapeutics to $76 from $56 and keeps a Buy rating on the shares. Following Trutakna's FDA approval, the outlook on Vera Therapeutics has improved with higher success assumptions, updated pricing and market share expectations, extended IP protection, and increased conf